









Supplementary figure 1 Forest plots of incidence of high-grade anemia (A), thrombocytopenia (B), leukopenia (C) and neutropenia (D) during PD-1 inhibitor monotherapy.



Supplementary figure 2 Forest plots of incidence of high-grade anemia during PD-1 inhibitor monotherapy for NSCLC (A), melanoma (B), RCC (C), urothelial carcinoma (D), and HNSCC (E).



Supplementary figure 3 Forest plots of incidence of all-grade leukopenia for NSCLC (**A**) and melanoma (**B**); all-grade neutropenia for NSCLC (**C**) and melanoma (**D**); all-grade thrombocytopenia for NSCLC (**E**) and melanoma (**F**) during PD-1 inhibitor monotherapy.



Supplementary figure 4 Funnel plots for PD-1 inhibitor monotherapy studies for all tumor types (**A**) and NSCLC (**B**) for anemia of all grades.